Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 1
1992 2
1993 1
1994 3
1995 4
1996 2
1997 5
1998 2
1999 3
2000 1
2001 5
2002 7
2003 4
2004 1
2005 3
2006 6
2007 9
2008 9
2009 2
2010 3
2011 4
2012 4
2013 5
2014 2
2015 2
2016 3
2017 6
2018 5
2019 6
2020 7
2021 11
2022 8
2023 1
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
AUTHOR REPLY.
Shenhar C, Veredgorn Y, Bulis S, Aviv T, Darawsha AE, Gilad R, Baniel J, Ehrlich Y, Lifshitz D. Shenhar C, et al. Among authors: gilad r. Urology. 2022 Jan;159:159. doi: 10.1016/j.urology.2021.06.056. Urology. 2022. PMID: 35027176 No abstract available.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Negative Pressure Wound Therapy in Spinal Surgery.
White AJ, Gilad R, Motivala S, Fiani B, Rasouli J. White AJ, et al. Among authors: gilad r. Bioengineering (Basel). 2022 Oct 26;9(11):614. doi: 10.3390/bioengineering9110614. Bioengineering (Basel). 2022. PMID: 36354525 Free PMC article. Review.
Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial.
Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, Roebling R; SP0982 co-investigators. Vossler DG, et al. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1067-1075. doi: 10.1136/jnnp-2020-323524. Epub 2020 Aug 18. J Neurol Neurosurg Psychiatry. 2020. PMID: 32817358 Free PMC article. Clinical Trial.
Lamotrigine and catamenial epilepsy.
Gilad R, Sadeh M, Rapoport A, Dabby R, Lampl Y. Gilad R, et al. Seizure. 2008 Sep;17(6):531-4. doi: 10.1016/j.seizure.2008.02.001. Epub 2008 Apr 16. Seizure. 2008. PMID: 18420429 Free article. Clinical Trial.
Myotonia in DNM2-related centronuclear myopathy.
Dabby R, Sadeh M, Gilad R, Jurkat-Rott K, Lehmann-Horn F, Leshinsky-Silver E. Dabby R, et al. Among authors: gilad r. J Neural Transm (Vienna). 2014 May;121(5):549-53. doi: 10.1007/s00702-013-1140-8. Epub 2013 Dec 24. J Neural Transm (Vienna). 2014. PMID: 24366529
129 results